Get the LJPC Research Report and
Also Receive Our Top Trades for 2017!

La Jolla Pharmaceutical Company

On February 27th, the company announced positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients with catecholamine resistant hypotension (CRH). “These study results support that angiotensin II, a molecule first synthesized by Dr. Irvine Page at the Cleveland Clinic, improves outcomes in distributive shock patients requiring high-dose catecholamines. Given the high mortality from this condition, it i … (See Research Report)
Download Research Report
on LJPC Now